Q2 FY2026 EarningsQ2 FY2026 results missed consensus on the top and bottom lines: revenue was $39.0M vs. $40.6M expected, and Non-GAAP gross margin fell to 36% vs. the 41.4% mean estimate. Lower instrument revenue and strategic pricing pressure on Revio systems were key drags. Despite cost-saving initiatives, a higher-than-expected Non-GAAP net loss of $41.9M was reported, while FY2026 revenue guidance remains cautious at $155M-$165M.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: Pacific Biosc California(PACB) the Revenue is 39.01 M (-1.91%), Miss estimate;the EBIT is -44.61 M (-1.64%), Miss estimate;the EPS is -0.14 (+0%), Miss estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
RevenueMiss expectations
0.04B1.91%
0.04B2.04%
-0.00B3.95%
EBITMiss expectations
-0.04B1.64%
-0.04B3.37%
-0.00B5.01%
EPSMiss expectations
-0.14--
-0.1381.43%
-0.00201.43%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf